Liquidia Technologies (LQDA)
NASDAQ:LQDA
Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$39.47
<$0.01(<0.01%)
At close: 4:00 PM EST
$39.47
<$0.01(<0.01%)
Day’s Range― - ―
52-Week Range$11.85 - $63.46
Previous CloseN/A
Volume97.81K
Average Volume (3M)1.46M
Market Cap
$4.90B
Enterprise Value$5.46B
Total Cash (Recent Filing)$222.79M
Total Debt (Recent Filing)$184.82M
Price to Earnings (P/E)217.4
Beta1.68
Next Earnings
Aug 06, 2026EPS Estimate
0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.24
Shares Outstanding88,928,100
10 Day Avg. Volume1,306,964
30 Day Avg. Volume1,464,315
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap1.11
Enterprise Value/Revenue18.96
Enterprise Value/Gross Profit20.66
Enterprise Value/Ebitda105.01
Forecast
1Y Price Target
$64.83Price Target Upside64.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)3.29
Revenue Forecast (FY)$714.04M
Bulls Say, Bears Say
Bulls Say
Commercial AdoptionAnalyst highlights rapid prescription uptake, an expanding prescriber base, and high patient conversion that suggest Yutrepia is driving new prostacyclin treatment starts and supporting stronger-than-expected revenue momentum.
Profitability And Earnings LeverageVery high gross margins combined with disciplined operating expenses and reported profitability create attractive earnings leverage that could draw interest from institutional and core healthcare investors.
Technology Differentiation And TolerabilityAnalyst and key opinion leaders note the proprietary PRINT inhalation technology produces more uniform, smaller particles that improve lung targeting, enable efficient high-dose titration, and reduce coughing compared with conventional dry powder inhalers.
Bears Say
Cash And Funding RiskCash resources appear limited relative to growth ambitions, creating the risk that additional financing will be required, which could dilute shareholders or constrain investment in commercial expansion.
Competitive Device Announcement RiskA partner's surprise unveiling of a new inhaled treprostinil device without supporting clinical data or direct comparisons has amplified investor concern about competitive dynamics and contributed to downward pressure on the share price.
Patent Litigation OverhangOngoing patent litigation over a key patent represents a material overhang that could trigger injunctions or label restrictions, increasing investor uncertainty and the potential for significant stock volatility.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies’s price range in the past 12 months?
Liquidia Technologies lowest stock price was $11.85 and its highest was $63.46 in the past 12 months.
What is Liquidia Technologies’s market cap?
Liquidia Technologies’s market cap is $4.90B.
When is Liquidia Technologies’s upcoming earnings report date?
Liquidia Technologies’s upcoming earnings report date is Aug 06, 2026 which is in 64 days.
How were Liquidia Technologies’s earnings last quarter?
Liquidia Technologies released its earnings results on May 11, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.11.
Is Liquidia Technologies overvalued?
According to Wall Street analysts Liquidia Technologies’s price is currently Undervalued.
Does Liquidia Technologies pay dividends?
Liquidia Technologies does not currently pay dividends.
What is Liquidia Technologies’s EPS estimate?
Liquidia Technologies’s EPS estimate is 0.79.
How many shares outstanding does Liquidia Technologies have?
Liquidia Technologies has 88,928,100 shares outstanding.
What happened to Liquidia Technologies’s price movement after its last earnings report?
Liquidia Technologies reported an EPS of $0.52 in its last earnings report, beating expectations of $0.41. Following the earnings report the stock price went up 25.603%.
Which hedge fund is a major shareholder of Liquidia Technologies?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$64.83 (64.26% Upside)
$64.83 (64.26% Upside)
Blogger Sentiment
Bullish
LQDA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 25.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $21.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 20.1%
Last 30 Days ▲ 20.1%
News Sentiment
Very Bearish
Bullish news 19%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.67%
12-Months-Change
Fundamentals
Return on Equity
46.82%
Trailing 12-Months
Asset Growth
76.55%
Trailing 12-Months
Company Description
Liquidia Technologies
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum: rapid revenue and profitability growth, expanding market share, growing prescription breadth and depth, and a well-funded clinical pipeline. Primary risks cited were legal uncertainty, the need for continued market education (especially in PH-ILD and community settings), dosing convenience considerations (addressable by L606), and timing of broader indication studies. Overall, positives substantially outweigh the challenges described.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$64.83
▲(64.26% Upside)
Technical Analysis
Ocular Therapeutix
―
Adaptive Biotechnologies
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
32.21% Insiders
8.35% Mutual Funds
39.17% Other Institutional Investors
10.33% Public Companies and Individual Investors